Bioceres Crop Solutions (BIOX) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
29 May, 2026Executive summary
Navigated a challenging period marked by weak commodity prices and tightened credit in Argentina, impacting revenues and working capital.
Maintained focus on operational performance, cash generation, and disciplined working capital management.
Board directed management to develop a three-year financial plan for the continuing business, excluding Pro Farm assets.
Financial highlights
Consolidated gross margin for the six months ended December 31, 2025, was 40%, consistent year-over-year.
Pro Farm assets classified as discontinued operations following foreclosure.
Outlook and guidance
Priorities include driving operational performance, improving cash generation, and maintaining working capital discipline.
Management is developing a comprehensive financial plan focused on profitability and cash flow.
Confidence in the technology platform and improving macroeconomic environment in Argentina.
Latest events from Bioceres Crop Solutions
- Revenue fell 23% to $39.4M, net loss $10M, $179M Pro Farm loss, litigation ongoing.BIOX
Q3 202612 May 2026 - FY24 revenue up 11% to $464.8M, with U.S. HB4 approval boosting future growth.BIOX
Q4 202421 Jan 2026 - Revenue dropped 20% to $93.3M, but gross margin rose to 40.2% amid global and product mix shifts.BIOX
Q1 202514 Jan 2026 - Over 15 million shares registered for resale by existing holders; no new capital raised.BIOX
Registration Filing16 Dec 2025 - Over 15 million shares registered for resale, supporting global growth in sustainable agri-biotech.BIOX
Registration Filing16 Dec 2025 - Revenue down 24% to $106.7M, gross margin up to 42%, shift to asset-light, partnership model.BIOX
Q2 20252 Dec 2025 - Revenue fell 28% but cash flow surged, driven by operational efficiencies and new product launches.BIOX
Q3 202520 Nov 2025 - Gross margin rose to 47% as revenue fell 17% and Adjusted EBITDA jumped 61% year-over-year.BIOX
Q1 202617 Nov 2025 - Revenue fell 28% and net loss reached $55.2M, but operating cash flow rose 27% year-over-year.BIOX
Q4 202511 Sep 2025